Pre-clinical studies support the benefit of transgenic cytokines like IL15 and IL7 in augmenting the CAR T cell anti-tumor response; first clinical trials are evaluating safety and efficacy of the approach (Table 1). The gene discussed is IL7; the disease is neoplasm.